Trial reportJournal of microbiology and biotechnology2026
Efficacy and Safety of Enzyme-Derived Deer Velvet Extract Supplementation on Adults with Chronic Fatigue: a Randomized, Placebo-Controlled, Double-Blind Trial.
Trial report in Journal of microbiology and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic Fatigue Syndrome (CFS) significantly impairs health-related quality of life in working-age populations, leading many individuals to use nutritional supplements for fatigue management. YC-1101, an enzymatically derived deer velvet extract, has demonstrated anti-fatigue potential in preclinical studies; however, clinical evidence in humans remains limited. This study aimed to evaluate the efficacy and safety of YC-1101 in adults with CFS. In an 8-week randomized controlled trial, 100 patients with CFS were assigned to either the YC-1101 or the placebo group. Subjective fatigue was assessed at baseline, at an interim point, and at the end of the intervention. Fatigue-related blood biomarkers and cardiorespiratory endurance were measured at baseline and postintervention. Compared with placebo, YC-1101 significantly improved Factor 1 (general and physical fatigue) of the Multidimensional Fatigue Inventory (MFI) at weeks 4 and 8, with a significant group-by-time interaction (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.